Thrombosis

Cardiovascular
12
Pipeline Programs
8
Companies
19
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
0
3
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
Alteplase "push" protocolPhase 41 trial
Active Trials
NCT00303420Terminated180Est. Dec 2008
Sanofi
SanofiPARIS, France
1 program
1
aspirin 75 mg/dayPhase 41 trial
Active Trials
NCT00190307Completed293Est. Dec 2009
Bristol Myers Squibb
4 programs
3
1
ApixabanPhase 21 trial
BMS-986177Phase 15 trials
BMS-986177Phase 11 trial
BMS-986177Phase 11 trial
Active Trials
NCT04965389Completed17Est. Oct 2021
NCT03939702Completed9Est. Jul 2019
NCT03698513Completed113Est. Feb 2019
+5 more trials
Pfizer
PfizerNEW YORK, NY
2 programs
1
1
ApixabanPhase 2
Apixaban IRPhase 1
DS
Daiichi SankyoChina - Shanghai
1 program
1
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitorPhase 21 trial
Active Trials
NCT00398216Completed903Est. Jun 2007
Aronora
AronoraOR - Portland
2 programs
2
E-WE Thrombin- Dose 1Phase 11 trial
xisomab 3G3- Dose 1Phase 11 trial
Active Trials
NCT03453060Completed21Est. Nov 2018
NCT03097341Completed21Est. Jan 2018
CSL Behring
CSL BehringIL - Bradley
1 program
1
KcentraPhase 1

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sanofiaspirin 75 mg/day
RocheAlteplase "push" protocol
Bristol Myers SquibbApixaban
Daiichi SankyoDU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
Bristol Myers SquibbBMS-986177
Bristol Myers SquibbBMS-986177
Bristol Myers SquibbBMS-986177
Bristol Myers SquibbBMS-986177
AronoraE-WE Thrombin- Dose 1
Bristol Myers SquibbBMS-986177
Bristol Myers SquibbBMS-986177
Bristol Myers SquibbBMS-986177
Bristol Myers SquibbBMS-986177
Bristol Myers SquibbBMS-986177
Aronoraxisomab 3G3- Dose 1

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 1,988 patients across 19 trials

NCT00190307Sanofiaspirin 75 mg/day

STRATAGEM: Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery

Start: Jun 2005Est. completion: Dec 2009293 patients
Phase 4Completed
NCT00303420RocheAlteplase "push" protocol

Alteplase for Blood Flow Restoration in Hemodialysis Catheters

Start: Sep 2004Est. completion: Dec 2008180 patients
Phase 4Terminated
NCT00320255Bristol Myers SquibbApixaban

A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

Start: Jun 2006Est. completion: Jan 2009130 patients
Phase 2Completed
NCT00398216Daiichi SankyoDU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor

A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery

Start: May 2006Est. completion: Jun 2007903 patients
Phase 2Completed
NCT03000673Bristol Myers SquibbBMS-986177

A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis

Start: May 2017Est. completion: Oct 201732 patients
Phase 1/2Completed
NCT04965389Bristol Myers SquibbBMS-986177

A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants

Start: Jul 2021Est. completion: Oct 202117 patients
Phase 1Completed
NCT03939702Bristol Myers SquibbBMS-986177

Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants

Start: May 2019Est. completion: Jul 20199 patients
Phase 1Completed
NCT03698513Bristol Myers SquibbBMS-986177

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

Start: Oct 2018Est. completion: Feb 2019113 patients
Phase 1Completed
NCT03453060AronoraE-WE Thrombin- Dose 1

Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

Start: May 2018Est. completion: Nov 201821 patients
Phase 1Completed
NCT02982707Bristol Myers SquibbBMS-986177

Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants

Start: Mar 2018Est. completion: Sep 201826 patients
Phase 1Completed
NCT03362437Bristol Myers SquibbBMS-986177

Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants

Start: Nov 2017Est. completion: Dec 201712 patients
Phase 1Completed
NCT03341390Bristol Myers SquibbBMS-986177

An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants

Start: Oct 2017Est. completion: Nov 201720 patients
Phase 1Completed
NCT03196206Bristol Myers SquibbBMS-986177

Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

Start: Jul 2017Est. completion: Mar 201824 patients
Phase 1Completed
NCT03224260Bristol Myers SquibbBMS-986177

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Start: Jun 2017Est. completion: Nov 201733 patients
Phase 1Completed
NCT03097341Aronoraxisomab 3G3- Dose 1

Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects

Start: Jun 2017Est. completion: Jan 201821 patients
Phase 1Completed
NCT02902679Bristol Myers SquibbBMS-986177

A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment

Start: Nov 2016Est. completion: Jun 20176 patients
Phase 1Completed
NCT02959060Bristol Myers SquibbBMS-986177

A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects

Start: Nov 2016Est. completion: Dec 201616 patients
Phase 1Completed
NCT02807909Bristol Myers SquibbBMS-986177

A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects

Start: Jul 2016Est. completion: Aug 201628 patients
Phase 1Completed
NCT02608970Bristol Myers SquibbBMS-986177

Safety and Tolerability Study of BMS-986177 in Healthy Subjects

Start: Dec 2015Est. completion: Jul 2017104 patients
Phase 1Completed

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Operator I

Abbott
United States - California - Pleasanton
Yesterday
$17 - $33/hr

Visitador (a) Médico

Abbott
Dominican Republic - Santo Domingo
Yesterday

Visitador Médico

Abbott
Nicaragua - Managua
Yesterday

Director, Strategic & Growth Marketing - Abbott Heart Failure

Abbott
United States - California - Pleasanton
Yesterday
$197K - $395K/yr

Clinical Specialist, Chronic MCS - Louisville, KY/Cincinnati, OH

Abbott
United States - Kentucky - Louisville
Yesterday
$61K - $123K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 companies competing in this space

Related Indications

Hypertension(361)Heart Failure(354)Coronary Artery Disease(306)Atrial Fibrillation(296)Pulmonary Arterial Hypertension(106)Acute Coronary Syndrome(67)Pulmonary Hypertension(57)Atherosclerosis(44)Hypertension, Pulmonary(34)Congestive Heart Failure(34)